【Breaking News】 Haibu Pharmaceutical appeared at the 89th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Trade Fair (API China)
Classification:
Company News
Release time:
2023-10-24
On October 18, 2023, the 89th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Trade Fair (API China) and the 27th China International Pharmaceutical (Industrial) Exhibition and Technology Exchange Conference (CHINA-PHARM) opened at the Nanjing International Expo Center, lasting for three days.
"Haibu Pharmaceutical" Building Dreams Together
Meeting at the right time, a new chapter is written in time! At the exhibition site, the Haibu API business team actively communicated and negotiated with new and old customers to understand industry development trends, cutting-edge technologies, etc., and conducted in-depth discussions on market information, product information, and business cooperation. The team's enthusiastic and professional service received high recognition from both new and old customers, laying a solid foundation for future cooperation.
This exhibition achieved zero-distance contact between products, technologies, and customers, providing new ideas and directions for future upgrades of Haibu Pharmaceutical's product quality and service quality.
In the future, Haibu Pharmaceutical will actively participate in international exhibitions to improve its global marketing network construction. With a more mature and professional service attitude, it will provide various services such as raw material drug-related declarations, commercial supply of pharmaceutical intermediates, CRO services for raw materials and formulations, joint MAH licensing services, etc. We look forward to sincere cooperation with industry colleagues to contribute to the prosperous development of the pharmaceutical industry.
Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as "Haibu Pharmaceutical") was established in 2005. It is a high-tech enterprise with "chemical drug research and development" as its core capability. It has a research center in Beijing, a pilot verification center for raw materials and formulations, and a GMP industrial production base. The company mainly engages in CRO services for raw materials and formulations, joint MAH licensing services, raw material drug-related declarations, as well as commercial supply of pharmaceutical intermediates. Its R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular diseases, digestive system diseases, respiratory system diseases.
Haibu Pharmaceutical has been awarded the title of "Top 20 Chinese Pharmaceutical R&D Companies" for several consecutive years and has been recognized as a "Specialized & Innovative Enterprise" by Beijing City; it is also designated as a "National High-tech Enterprise," "Beijing Science & Technology Research Development Institution," "Beijing Yizhuang Enterprise Innovation Center," among others.
Beijing Hope Pharmaceutical Co., Ltd.
